FDA Approves Vesicare (solifenacin succinate) for the Treatment of Overactive Bladder
Vesicare (solifenacin succinate) is a muscarinic receptor antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, frequency, and urge incontinence.
Posted: November 2004
Related articles
- FDA Approves VESIcare LS (solifenacin succinate) Oral Suspension for Neurogenic Detrusor Overactivity (NDO) Pediatric Patients - May 27, 2020
VESIcare (solifenacin succinate) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
